From "Special K" to "Special M": The Evolution of the Recreational Use of Ketamine and Methoxetamine

CNS Neuroscience and Therapeutics

Volumn 19, Issue 6, 2013, Pages 454-460

  Corazza, Ornella ^a   Assi, Sulaf ^a   Schifano, Fabrizio ^a  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Ketamine; Methoxetamine; Near death experience; Phencyclidine; Psychoactive

Indexed keywords

ALCOHOL; AMINE; CANNABIS; KETAMINE; LYSERGIDE; METHOXETAMINE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RECREATIONAL DRUG; SEROTONIN UPTAKE INHIBITOR; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

AGITATION; ALCOHOL CONSUMPTION; ANTIDEPRESSANT ACTIVITY; BLADDER DISEASE; CANNABIS SMOKING; CARDIOVASCULAR DISEASE; CHEMICAL MODIFICATION; CONFUSION; DEPERSONALIZATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG MISUSE; DRUG RECEPTOR BINDING; DRUG TOLERANCE; EMPATHY; EUPHORIA; FUNCTIONAL DISSOCIATION; HALLUCINATION; HUMAN; INTERSTITIAL CYSTITIS; INTROSPECTION; LIVER DYSFUNCTION; MEMORY DISORDER; MOOD DISORDER; NECROSIS; NEUROTOXICITY; PERCEPTION DISORDER; REVIEW; SUICIDE ATTEMPT; URETER OBSTRUCTION; URINARY TRACT DISEASE; WITHDRAWAL SYNDROME;

CYCLOHEXANONES; CYCLOHEXYLAMINES; HUMANS; KETAMINE; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84878198012     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12063     Document Type: Review

References (61)

1. Rowland LM. Sub-anesthetic ketamine: how it alters physiology and behavior in humans. Aviation Space Environ Med 2005;76:C52-C58.
2. Goldberg ME, Torjman MC, Schwartzman RL, Mager DE, Wainer IW. Enantioselective pharmacokinetics of (R)- and (S)-ketamine after a 5-day infusion in patients with complex regional pain syndrome. Chirality 2011;23:138-143.
3. Curran HV, Morgan C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction 2000;95:575-590.
4. Quibell R, Prommer EE, Mihalyo M, Twycross R, Wilcock A. Ketamine*. J Pain Symptom Manage 2011;41(3):640-649.
5. Meller ST. Ketamine: relief from chronic pain through actions at the NMDA receptor? Pain 1996;68:435-436.
6. Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR. Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. Eur Neuropsychopharmacol 2012;22:308-317.
7. Corazza O, Schifano F, et al. The phenomenon of new drugs on the Internet: a study on the diffusion of the ketamine derivative methoxetamine ('MXE'). Hum Psychopharmacol Clin Exp 2011;27:145-149.
8. Bonta IL. Schizophrenia, dissociative anaesthesia and near-death experience; three events meeting at the NMDA receptor. Med Hypotheses 2004;62:23-28.
9. Collier BB. Ketamine and the conscious mind. Anaesthesia 1972;27:120-134.
10. Sehdev RS, Symmons DAD, Kindl K. Ketamine for rapid sequence induction in patients with head injury in the emergency department. Emerg Med Australas 2006;18:37-44.
11. Bell R, Dahl J, Moore R, Kalso E. Perioperative ketamine for acute postoperative pain. Emerg Med Australas 2006;18:37-44.
12. Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs 2007;39:13-19.
13. Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs 1997;29:165-183.
14. Krystal JH, Petrakis IL, Krupitsky E, Schutz C, Trevisan L. D"Souza DC. NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy. Ann N Y Acad Sci 2003;1003:176-184.
15. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012;338:68-72.
16. Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handb Exp Pharmacol 2012;213:267-295.
17. Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull 2012;38:958-966.
18. Schifano F, Corkery J, Oyefeso A, Tonia T, Ghodse AH. Trapped in the "K-hole": overview of deaths associated with ketamine misuse in the UK (1993-2006). J Clin Psychopharmacol 2008;28:114-116.
19. Corazza O, Schifano F. Ketamine use: a prospective study on the emergence of near-death states among a group of 50 ketamine recreational users. Subst Use Misuse 2010;45:916-924.
20. Stevenson C. Ketamine: A review, 2003. Update in Anesthesia: http://update.anaesthesiologists.org/wp-content/uploads/2009/08/Ketamine -A-Review.pdf (retrieved on October 2nd, 2012).
21. Goldberg ME, Torjman MC, Schwartzman RJ, Mager DE, Wainer IW. Pharmacodynamic Profiles of Ketamine (R)-and (S)- with 5-Day Inpatient Infusion for the Treatment of Complex Regional Pain Syndrome. Pain Physician 2010;13:379-387.
22. Clements JA, Nimmo WS, Grant S. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 1982;71:539-542.
23. DrugsForum. Available from: http://www.Drugs-Forum.com/forum/showwiki.php?title=N-ethyl-nor-ketamine (accessed on November 28th, 2012).
24. Beagle JQ. Synthesis and Effects of PCP Analogs; A review by John Q. Beagle. Available from: http://www.erowid.org/archive/rhodium/chemistry/pcp/ (accessed on November 28th, 2012).
25. The Independent. Ketamine tops cocaine as new drug of choice, 2009. http://www.independent.co.uk/news/uk/home-news/ketamine-tops-cocaine-as- new-drug-of-choice-1366714.html (retrieved on August 29th, 2012).
26. Morgan CJA, Monaghan L, Curran V. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction 2004;99:1450-1461.
27. Jansen KLR. Ketamine: Dreams and Realities. Sarasota, FL: MAPS, 2011.
28. Greyson B, Stevenson I. The phenomenology of near-death experiences. Am J Psychiatry 1980;137:1193-1196.
29. Jansen KLR. Near-Death Experiences and the NMDA receptor. BMJ 1989;298:1708.
30. Corazza O. Near-Death Experiences: Exploring the Mind-Body connection. London/New York: Routledge, 2008.
31. Van Lommel P, Van Wees R, Meyers V, Elfferich I. Near-death experience in survivors of cardiac arrest: a prospective study in the Netherlands. Lancet 2001;358:2039-2045.
32. Persinger M. Religious and mystical experiences as artefacts of temporal lobe function: a general hypothesis. Percept Mot Skill 1983;57:1255-1262.
33. Comer NL, Madow L, Dixon JL. Observation of sensory deprivation in a life-threatening situation. Am J Psychiatry 1967;124:164-169.
34. Blanke O, Ortigue S, Landis T, Seeck M. Stimulating illusory own body perceptions. Nature 2002;419:269-270.
35. Moody RA. Life after Life. Atlanta, GA: Mockingbird Books, 1975.
36. Fenwick P. Is the near-death experience only N-methyl-d-aspartate blocking? J Near Death Stud 1997;16:43-53.
37. EMCDDA: Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs, European Monitoring Centre for Drugs and Drug Addiction, 2002.
38. Dalgarno P, Shewan D. Illicit use of ketamine in Scotland. J Psychoactive Drugs 1996;28:191-199.
39. Wood D, Cottrell A, Baker SC, et al. Recreational ketamine: from pleasure to pain. BJUI 2011;197:1881-1884.
40. Morgan CJA, Mofeez A, Brandner B, Bromley L, Curran V. Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study. Psychopharmacology 2004;172:298-308.
41. Morgan CJA, Mofeez A, Brandner B, Lesley B, Curran V. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 2004;29:208-218.
42. Krystal J, Karper L, Seibyl J, et al. Subanaesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans". Arch Gen Psychiatry 1994;51:199-214.
43. Malhotra A, Pinals D, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996;14:301-308.
44. Siegal R. Phencyclidine and ketamine intoxication: a study of four populations of recreational users. In: Peterson RC, Stillman RC, editors. Phencyclidine Abuse: An Appraisal (Natl. Inst. Drug Abuse Res. Monogr. 21). Rockville, MD: National Institute of Drug Abuse, 1978;119-147.
45. Bhattacharya S. New Scientist, Chronic ketamine use kills bladder cells, 2011. http://www.newscientist.com/article/mg21028174.100-chronic-ketamine-use- kills-bladder-cells.html (retrieved August 29th, 2012).
46. Colebunders B, Van Erps P. Cystitis due to the use of ketamine as a recreational drug: a case report. JMCR 2008;2:219.
47. Wood DM, Davies S, Puchnarewicz M, Johnston A, Dargan PI. Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur J Clin Pharmacol 2012;68:853-856.
48. Assi S, Fergus S, Stair JL, Corazza O, Schifano F. Emergence and identification of new designer products from the internet. Eur Pharm Rev 2011;16:68-72.
49. ACMD, 2012. http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/s tatement-methoxetamine?view=Binary (accessed on August 29th, 2012).
50. Wood DM, Dargan PI. Novel psychoactive substances: how to understand the acute toxicity associated with the use of these substances. Ther Drug Monit 2012;34:363-367.
51. drugs-forum, 2011. Retrieved on September, 2012, from http://www.drugs-forum.com/index.php.
52. LoGiCal Analytical Monograph Methoxetamine, 2012. http://www.logical-standards.com/uploads/pdfs/english/Methoxetamine_Fina l.pdf (accessed on August 29th, 2012).
53. Bluelight, 2010. Retrieved on September 2012, from http://www.bluelight.ru/vb.
54. Drugs-Forum, 2010. Retrieved on September, 2012, from: http://www.drugs-forum.com/index.php.
55. Coull J, Morgan H, Cambridge V, et al. Ketamine perturbs perception of the flow time in healthy volunteers. Psychopharmacology (Berl) 2011;218:543-556.
56. Purechemicals, 2010. Retrieved on September 2012, from: http://www.purechemicals.co.uk.
57. Bluelight, 2011. Retrieved on September 2012, from http://www.bluelight.ru/vb.
58. Dillon P, Copeland J, Jansen K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend 2003;69:23-28.
59. Fletcher P, Honey GD. Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits. Trends Cogn Sci 2006;10:167-174.
60. Shields JF, Dargan PI, Wood DM, Puchnarewicz M, Davies S, Waring WS. Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation. Clin Toxicol (Phila) 2012;50:438-440.
61. Bluelight, 2012. Retrieved on September 2012, from http://www.bluelight.ru/vb.